By: Kairos Ventures On: October 13, 2020 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its...

Read more
By: Kairos Ventures On: June 23, 2020 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of...

Read more
By: Kairos Ventures On: June 18, 2020 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for...

Read more
By: Kairos Ventures On: June 10, 2020 In: Linnaeus, Portfolio News

Linnaeus Therapeutics, Inc. announced that its scientific co-founders, Christopher Natale, PhD, Vice President of Research at Linnaeus and Todd...

Read more
By: Kairos Ventures On: September 25, 2019 In: Linnaeus, Portfolio News

Congratulations to Linnaeus for receiving clearance from the FDA for the company's investigational new drug application (IND) for LNS8801...

Read more
By: Kairos Ventures On: September 23, 2019 In: Linnaeus, Portfolio News

We are delighted to announce that Linnaeus Therapeutics, Inc. has closed a $12 million series B financing led by...

Read more
By: Kairos Ventures On: November 13, 2018 In: Linnaeus, Portfolio News

We are pleased to announce that Linnaeus Therapeutics is the latest company to join the Kairos portfolio. Linnaeus Therapeutics...

Read more